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Abstract
The transmissible agent of prion disease consists of a prion protein in its abnormal, b-sheet rich state (PrP
Sc), which is
capable of replicating itself according to the template-assisted mechanism. This mechanism postulates that the folding
pattern of a newly recruited polypeptide chain accurately reproduces that of a PrP
Sc template. Here we report that authentic
PrP
Sc and transmissible prion disease can be generated de novo in wild type animals by recombinant PrP (rPrP) amyloid
fibrils, which are structurally different from PrP
Sc and lack any detectable PrP
Sc particles. When induced by rPrP fibrils, a long
silent stage that involved two serial passages preceded development of the clinical disease. Once emerged, the prion
disease was characterized by unique clinical, neuropathological, and biochemical features. The long silent stage to the
disease was accompanied by significant transformation in neuropathological properties and biochemical features of the
proteinase K-resistant PrP material (PrPres) before authentic PrP
Sc evolved. The current work illustrates that transmissible
prion diseases can be induced by PrP structures different from that of authentic PrP
Sc and suggests that a new mechanism
different from the classical templating exists. This new mechanism designated as ‘‘deformed templating’’ postulates that a
change in the PrP folding pattern from the one present in rPrP fibrils to an alternative specific for PrP
Sc can occur. The
current work provides important new insight into the mechanisms underlying genesis of the transmissible protein states
and has numerous implications for understanding the etiology of neurodegenerative diseases.
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Introduction
Prion diseases, or transmissible spongiform encephalopathies
(TSEs), are fatal neurodegenerative disorders that can be sporadic,
inherited, or infectious in origin. Misfolding and aggregation of the
normal, cellular form of the prion protein (PrP
C) into an abnormal
b-sheet rich state underlies the pathogenic mechanisms of the
prion diseases for all three origins [1]. The ‘‘protein only’’
hypothesis of prion propagation postulates that the transmissible
agent of prion diseases consists of a prion protein in its abnormal,
b-sheet rich conformation (PrP
Sc), which is capable of propagating
itself in an autocatalytic manner by recruiting and converting PrP
C
[2,3].
Recent years have witnessed a number of studies where
transmissible prion diseases were generated in animals de novo by
inoculating prion infectious material produced in vitro [4–10]. All
studies on generating prion infectivity can be divided into two
large groups, where the materials for inoculating animals were
produced using either (i) Protein Misfolding Cyclic Amplification
(PMCA) [8–10], or (ii) in vitro fibrillation protocols that utilized
recombinant PrP (rPrP) [4–7]. In the studies that employed the
first approach, application of serial PMCA (sPMCA) accomplished
two purposes: (i) generating PrP
Sc particles de novo and (ii)
amplification of newly formed PrP
Sc to amounts that can
effectively produce clinical disease in wild type animals within a
short incubation time and 100% success rate [8–10]. Because de
novo generation of PrP
Sc in sPMCA followed stochastic behavior, it
remains unclear whether a large amount of infectivity produced
after multiple rounds of sPMCA was a result of amplification of a
few or even a single PrP
Sc particle. In the second approach, rPrP
was converted into amyloid fibrils in vitro without application of
PMCA [4–7]. In these studies, transmissible diseases were
generated either in transgenic animals with high levels of PrP
C
expression and after relatively long incubation time [4,5,7], or in
wild type animals, but with a less than 100% success rate and after
a long silent stage [6]. Critical concerns that rPrP amyloid fibrils
did not induce the disease de novo but only accelerated an on-going
pathogenic process have been raised regarding the studies
performed on transgenic mice [11–13]. For the experiments
conducted on wild type animals, a long silent stage and less than
100% success rate led to the general assumption that the
preparations of amyloid fibrils contain minuscule amounts of
PrP
Sc or particles with a structure of PrP
Sc, and that this tiny sub-
fraction is responsible for the disease.
In the current study we report that no PrP
Sc can be detected in
preparations of rPrP amyloid fibrils using a sPMCA format that
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002419could detect as little as a single PrP
Sc particle. Nevertheless, despite
lack of PrP
Sc in the preparations of rPrP fibrils, transmissible prion
disease was produced in wild type animals. When induced by rPrP
fibrils, which are known to be structurally different from PrP
Sc
[14–17], the clinical disease developed only at the third serial
passage. The long silent stage to the disease that involved two
serial passages was found to be accompanied by significant
changes in biochemical and neuropathological properties of the
proteinase K (PK) -resistant PrP (PrPres). These changes involved
dramatic transformation of a PK-resistant profile, changes in the
PrPres deposition pattern and expansion of brain areas targeted by
PrPres. Clinical, neuropathological, and biochemical features of
the new prion disease were different from those produced in
rodents by previously known, hamster-adapted prion strains or
strains generated by sPMCA [8–10], consistent with the idea that
the new strain originated from a unique amyloid structure. The
current work introduces a new hypothesis that transmissible prion
diseases can be induced by cross-b PrP structures substantially
different from that of authentic PrP
Sc. This hypothesis suggests
that a new templating mechanism (which will be referred to as
‘‘deformed templating’’) different from the classical templating
might exist. The deformed templating involves a switch from one
PrP folding pattern present in amyloid fibrils to an alternative
folding pattern present in PrP
Sc. The current work provides
important new insight into the mechanisms underlying genesis and
evolution of the transmissible states of the prion protein and has
numerous implications for understanding the etiology of prion and
other neurodegenerative diseases.
Results
Serial transmission of rPrP amyloid fibrils
Full-length Syrian hamster rPrP was converted into amyloid
fibrils in vitro and subjected to an annealing procedure (brief
heating to 80uC) in the presence of BSA prior to inoculation as
previously described [6,18]. All experiments on expression and
purification of rPrP, its conversion into fibrils, annealing and
preparation of inocula were performed in a facility and with
equipment that have never been exposed to TSEs. Annealed rPrP
fibrils were inoculated intracerebrally into Syrian hamsters. While
none of the animals developed any signs of prion disease for up to
661 days post inoculation, one out of seven animals showed
atypical, PK-resistant, low molecular weight (LMW) bands of 21,
16 and 13 kDa ([6] and Figure 1A). These PK-resistant material
(PrPres) could be detected by the antibodies against the C-terminal
PrP region R1 (epitope 225–231) or SAF-84 (epitope 160–170),
but not by 3F4 (epitope 109–112) (Figure 1A and B). Interestingly,
when used as seed in sPMCA reaction with beads (sPMCAb) [19] ,
the brain material with atypical PrPres gave rise to PK-resistant
products with a band-shift typical for authentic PrP
Sc that could be
detected by 3F4 and the C-terminal antibodies (Figure 1C). These
PK-resistant products will be referred to as typical or standard
PrPres. We do not know whether it was atypical PrPres that gave
rise to typical PrPres in sPMCAb or small, undetectable amounts
of typical PrPres that might have already been present in brain
homogenates (BH).
BHs from the remaining six animals that lacked any PrPres
material on Western blot were tested in PMCAb. After a single
PMCAb round, BH from one more animal showed PrPres
products detectible by 3F4 antibody (Figure S1A). By the sixth
sPMCAb round, BH from an additional animal showed PrPres
positive by 3F4 antibody (Figure S1B). Ten non-seeded sPMCAb
reactions were all negative after six sPMCAb rounds (Figure S1C)
arguing against possibility of cross-contamination or generation of
PrP
Sc or PrPres de novo in the sPMCAb format employed here. As
we reported previously, sPMCAb reactions seeded with normal
BHs (NBHs) from old animals were also all negative after six
sPMCAb rounds [19]. Therefore, three out of seven animals
inoculated with rPrP fibrils showed signs of infection as judged by
appearance of PMCAb-active PrPres material in their brains,
although the amounts of PrPres material was highly variable. As
previously described, no clinical signs or PrPres material were
found in animals inoculated with any of the controls or in
uninoculated age-matched controls ([6] and Table S1).
To perform a second passage, 10% BH containing atypical
PrPres was inoculated into a new group. Surprisingly, none of the
animals developed clinical signs of the disease before they were
euthanized at 661 days (Table S1). However, six out of seven
hamsters showed large amounts of standard and atypical PrPres
(Figures 1B and S2). The remaining animal showed predominantly
atypical, LMW PrPres detectible by SAF-84 antibody and
miniscule amounts of standard PrPres (Figure S2, lane 6). After
a single PMCAb round, BH from this animal showed PrPres
products detectible by 3F4 antibody (Figure S2, lane 9). These
results illustrated that all animals were infected in a second
passage. The variation in the ratio of standard to atypical PrPres in
animals from the 2
nd passage (Figure S2) suggested that
transformation in PrPres structure and PK-resistance pattern
occurred at a variable rate within the same group of animals.
Considering that no clinical signs were observed despite substantial
amounts of PrPres, the new synthetic strain was designated as
LOTSS (LOw Toxicity Synthetic Strain).
The amount of PrPres in LOTSS-infected animals from the 2
nd
passage was similar to those found at the terminal stage of 263 K-
inoculated hamsters (Figure 1B). While no signs of clinical disease
were observed, LOTSS PrPres from the 2
nd passage showed
biochemical attributes of authentic PrP
Sc. LOTSS standard PrPres
could be amplified in sPMCAb and displayed an amplification rate
similar to that of 263 K PrP
Sc (Figure S3A). The resistance of
LOTSS standard PrPres to PK digestion was similar to that of
263 K (Figure S3B).
Histopathological studies of animals from the 2
d passage of
LOTSS revealed characteristic signs of TSE infection including
spongiform degeneration, neuronal loss, reactive astrogliosis and
deposition of disease-associated PrP in the brains and spinal cords
Author Summary
The transmissible agent of prion disease consists of a prion
protein in its abnormal conformation (PrP
Sc), which
replicates itself according to the template-assisted mech-
anism. This mechanism postulates that the folding pattern
of a newly recruited polypeptide chain accurately repro-
duces that of a PrP
Sc. The current study reports that
infectious prions and transmissible prion disease can be
triggered in wild type animals by amyloid fibrils produced
from recombinant prion prtotein, which are structurally
different from PrP
Sc and lacks any detectable PrP
Sc
particles. This work introduces a new hypothesis that
transmissible prion diseases can be induced by prion
protein structures different from that of authentic PrP
Sc
and suggests that a new mechanism for triggering PrP
Sc
formation different from the classical templating exists.
The current work provides important new insight into the
mechanisms underlying genesis and evolution of the
transmissible states of the prion protein and has numerous
implications for understanding the etiology of prion and
other neurodegenerative diseases.
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brains and no immunoreactivity for disease-associated PrP was
found in the spleens (data not shown). Spongiform change,
neuronal loss, and reactive astrogliosis were predominantly found
in the thalamus and the brainstem followed by caudate-putamen
and spinal cord, however, they were minor in the frontal cortex,
hippocampus or cerebellum (Figure 3A and C). Similar to the
animals infected with SSLOW, a synthetic strain that was
previously produced as a result of inoculation of NBH-annealed
rPrP fibrils [6], LOTSS-infected brains from the 2
nd passage
displayed prominent, large plaques and amorphous deposits in the
subpial, periventricular and periaqueductal subependymal regions
(Figures 2 and 3). Only mild synaptic PrP immunoreactivity was
found in the thalamus, brainstem, caudate-putamen and spinal
cord, while no noticeable synaptic PrP deposition was observed in
frontal cortex, hippocampus, or cerebellum (Figures 2 and 3C).
Previously, synaptic PrP immunoreactivity was defined as a type of
disease-associated PrP that co-localizes with synaptophysin [20].
Overall, the lesion profile and the pattern of PrP immunostaining
was reminiscent of those observed in SSLOW-inoculated animals
[6], but significantly different from those in 263 K-infected brains.
Differences between LOTSS and SSLOW
In previous studies, we showed that serial passaging of rPrP
fibrils annealed in NBH in Syrian hamster produced a synthetic
strain (designated as SSLOW) with highly unique clinical and
neuropathological features [6]. To test whether LOTSS is
different from SSLOW or 263 K, we employed a conformational
stability assay that monitors GdnHCl-induced denaturation using
3F4, D18 and SAF-84 antibodies that recognize PrP regions 109–
112, 133–157 and 160–170, respectively (Figure 4). Consistent
with previous study [21], the denaturation profiles monitored by
three antibodies were superimposable for 263 K (Figure 4A). This
result suggests that 263 K follows apparent two-state unfolding
without notable stable intermediates. In contrast to 263 K,
SSLOW showed a dissociation of the denaturation profile
monitored by SAF-84 from those monitored by 3F4 or D18
(Figure 4B), while LOTSS exhibited dissociation of the profiles
monitored by D18 and SAF-84 from that of 3F4 (Figure 4C).
This experiment revealed that (i) three strains showed three
individual strain-specific unfolding patterns; (ii) SSLOW and
LOTTS exhibited more complex unfolding behavior than 263 K,
(iii) in LOTSS, the central and the C-terminal domain were
found to be more stable than the N-terminal domain.
Furthermore, the region tracked by D18 antibody was found to
be considerably more stable in LOTSS than in SSLOW or
263 K. An alternative experimental format of the conformational
stability assay that employs PK-digestion and Western blot
instead of dot blot confirmed that three strains were conforma-
tionally different (Figure S4).
Figure 1. Serial passages of rPrP fibrils and de novo generation of PrP
Sc in Syrian hamsters. (A) Western blotting of brain homogenate
(BH) from the animal inoculated with BSA-annealed rPrP amyloid fibrils. Western blots were stained with 3F4 (left panel) or R1 (right panel) antibody.
Undigested samples were loaded at 1/10
th the amount of the digested samples. (B) Western blotting of BHs of animals from the 1
st,2
nd,o r3
rd
passages of BSA-annealed rPrP fibrils (lanes 1, 2 and 3, respectively) stained with 3F4 (top panel) or SAF-84 (bottom panel) antibody. The new prion
strain produced as a result of inoculation of BSA-annealed rPrP fibrils will be designated as LOTSS. The 1
st,2
nd,o r3
rd passages of SSLOW, the strain
that was previously produced as a result of inoculation of normal BH (NBH)-annealed rPrP fibrils (lanes 4, 5 and 6 respectively) [6], or 263 K are
provided as references. (C) sPMCAb of brain material from the 1
st passage of LOTSS. 10% BH from the animal inoculated with BSA-annealed rPrP
amyloid fibrils was diluted 10-fold into 10% RNA-depleted (NBH(-RNA)) or NBH and subjected to sPMCAb. Each PMCAb round consisted of 48 cycles,
30 min each; 10-fold dilutions were used for each subsequent sPMCAb round. Western blots were stained with 3F4 (top panel) or SAF-84 (bottom
panel) antibody. Undigested 10% NBH is provided as a reference.
doi:10.1371/journal.ppat.1002419.g001
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PLoS Pathogens | www.plospathogens.org 3 December 2011 | Volume 7 | Issue 12 | e1002419Figure 2. Analysis of PrP deposition in LOTSS-inoculated animals from the 2d passage. (A, B) PrP plaques in the subependymal regions
and minor synaptic immunoreactivity in the basal ganglia and thalamus. (C, D) PrP plaques in the subependymal regions in hippocampus and frontal
cortex. (E, F) Very minor focal PrP deposition in cerebellum. (G, H) Plaques around the aqueductus and synaptic PrP immunoreactivity in the
posterior and anterior horns of spinal cord.
doi:10.1371/journal.ppat.1002419.g002
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PLoS Pathogens | www.plospathogens.org 4 December 2011 | Volume 7 | Issue 12 | e1002419Figure 3. Histopathological analysis of brains of LOTSS-inoculated animals. Lesion profile (A) and PrP immunopositivity score (B) for
hamsters from the 2
nd (o, red lines) or 3
rd passages (D, black lines) of LOTSS. The histopathological profiles for SSLOW-inoculated hamsters (2
nd
passage, e blue line) were previously described in [6] and are provided as a reference. The lesion profile was obtained by averaging the scores for
spongiform change, neuronal loss and gliosis for three animals within each group. (C) Comparison of spongiform changes in the hippocampus,
frontal cortex, thalamus, and cerebellum stained with Hematoxylin and Eosin (H&E; upper panels) or anti-PrP 3F4 antibody (lower panels) in hamsters
from 2
nd or 3
rd passages of LOTSS, as indicated. Insets in H&E stained images of the frontal cortex and thalamus from LOTSS 2
nd animals represent
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LOTSS was found to be different from SSLOW or 263 K with
respect to the ratio of intensities of SAF-84 to 3F4 immunostain-
ing. Regardless of whether BHs were treated with PK or not and
regardless of whether Western blot or dot were used for analysis,
LOTSS-infected BHs consistently showed substantially higher
ratios of SAF-84 to 3F4 intensities than SSLOW or 263 K (Figures
S5 and 1B).
RNA-dependency emerged during the first passage
Previous studies established that RNA serves as a cofactor in
replication of hamster prion strains [22,23]. Furthermore,
formation of authentic mammalian PrP
Sc in vitro de novo from
purified PrP
C or rPrP was also shown to require RNA [9,10].
Because the current study employed the fibrillation protocols that
lacked RNA or any other cellular components, rPrP amyloid fibrils
did not require RNA for forming or self-propagating their
individual cross-b structures [18]. Therefore, we were interested
in testing whether RNA-dependency evolved with a transforma-
tion of rPrP amyloid structure into a structure of PrPres. To
address this question, sPMCAb reactions were seeded with BH
that contained atypical PKres products from the 1
st passage, and
amplification was carried out using normal or RNA-depleted BHs
as a source of PrP
C. In the presence of RNA, a gradual increase in
the amounts of standard, 3F4-positive PrPres material was
observed with each subsequent round (Figure 1C). This result
illustrates that in the presence of RNA, LOTSS PrPres
amplification rate exceeded 10-fold per round. However, in
RNA-depleted BH, the amounts of PrPres decreased with each
subsequent round and disappeared below detectable levels by the
5
th round suggesting that the amplification rate was less than 10-
fold per round (Figure 1C). In our experience, this amplification
rate was similar to the rate displayed by 263 K in RNA-depleted
NBH (data not shown). Therefore, in contrast to amyloid
fibrillation reactions, the amplification of LOTSS PrPres showed
a strong RNA-dependency, just like amplification of other hamster
strains [23]. Notably, an increase in PK-resistant material during
PMCAb was entirely attributed to the amplification of standard
PrPres, whereas no detectible amplification of the atypical PrPres
that produces 13- or 16-kDa PK-resistant bands was observed
regardless of the presence or absence of RNA. Overall, this
experiment revealed that the transformation from the RNA-
independent structure of amyloid fibrils to an RNA-dependent
structure of LOTSS PrPres occurred during the first passage.
Evolution of LOTSS neuropathological and biochemical
features during serial transmission
Despite substantial amounts of PrPres in the brains and the fact
that LOTSS PrPres exhibits key physical attributes of authentic
PrP
Sc, LOTSS-infected animals remained healthy in the second
passage. There is a possibility that the clinical signs associated with
LOTSS were not clearly visible and only involved impairment of
cognitive functions. Lack of clinical signs typical for TSEs might
indicate that LOTSS is an intrinsically silent strain, i.e. it is
characterized by transmissible formation of PrPres that displays
minimal neurotoxicity. Alternatively, LOTSS might not be silent
but the second passage represents a silent stage in evolution of
LOTSS pathological features. To distinguish between these
alternatives, a third passage was conducted. The very first clinical
signs of the disease including startle response to sound and touch
were noticed starting from 10
th to 12
th months post inoculation.
Similarly to SSLOW-inoculated animals, the progression of
disease in LOTSS-infected animals was very slow. After the first
signs, 5 to 8 months were required for the disease to progress to the
terminal stage (Table S1). Overall, the set of clinical symptoms was
similar to that of SSLOW strains (severe obesity, dry hair and hair
loss, difficulty in righting, substantially reduced activity) but
different from previously described hamster strains.
Three animals were analyzed at 307 days postinoculation, at
which two animals were yet asymptomatic, while the third one
began to show the first signs. While the PrPres amount varied
between these three animals, with the largest amount observed in
GFAP immunostaining, and enlargement of the PrP immunostaining. (D) Brain subependymal region stained with H&E and 3F4 antibody in LOTSS-
inoculated animals from 2
nd (left panel) or 3
rd (right panel) passages. Scale bar=00 mmi nC and=60 mmi nD.
doi:10.1371/journal.ppat.1002419.g003
Figure 4. Analysis of epitope-specific conformational stability.
Conformational stability profiles for 263 K (A), SSLOW (B), or LOTSS (C)
monitored in GdnHCl-induced denaturation assay using 3F4 (N, blue),
D18 (&, red) or SAF-84 (m, green) antibodies. Data represent average 6
SD of four denaturation experiments. Brain materials from SSLOW- or
LOTSS-inoculated animals from the 2
nd passages were used. 96-well dot
blot was used instead of Western blot for quantitative analysis of
multiple replicas in a single blot assay.
doi:10.1371/journal.ppat.1002419.g004
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(positive for SAF-84) to standard PrPres (positive for 3F4 and SAF-
84) remained approximately the same and was similar to those
observed in majority of animals at the end of the 2
nd passage
(Figure 5A). Because of the complexity in the PKres profile and,
specifically, the overlap between the upper 21 kDa band of
atypical PrPres with the middle band of standard PrPres, the
dynamics in PrPres profile is shown in parallel as a schematic
diagram (Figure 5B). The variation in the total PrPres amounts by
307 days was similar to the range seen at the end of life on the 2
nd
passage (Figure 5A).
The remaining animals of the 3
rd passage were euthanized
between 485 and 568 days postinoculation, as they approached
the terminal stage (Table S1). Only a very modest if any increase
in the total amount of PrPres was observed during the progression
of clinical disease (Figure 5A). Surprisingly, the relative ratio of
atypical to standard PrPres changed dramatically within the
clinical stage (Figure 5A). As judged from the disappearance of the
16 and 13 kDa bands, atypical PrPres was fully replaced by
standard PrPres as the clinical disease progressed to the terminal
stage.
Overall, the atypical PrPres was observed during three serial
passages, however, its amount diminished to undetectable levels
during the 3
rd passage clinical stage (Figures 1B and 5). While the
atypical PrPres was capable of replicating in a brain, this isoform
was not amplifiable under standard sPMCAb conditions
(Figure 1C). This first signs of standard PrPres appeared in the
first passage, although at the levels detectible only by PMCAb, but
not Western blotting (Figure 1A and C). While the accumulation
rate of standard PrPres varied between animals within the same
group (Figure S2), the amount of standard PrPres continued to
increase gradually during the 2
nd and 3
rd passages until it fully
replaced the atypical PrPres by the end of the 3
rd passage.
Neuropathological analysis of animals euthanized at 307 days
postinoculation in a 3
rd passage revealed plaques and granular PrP
deposits in the subpial, periventricular, and subependymal areas,
as well as fine perineuronal and synaptic PrP immunoreactivity in
thalamus and basal ganglia (Figure 6). These features were similar
to those observed in LOTSS-inoculated animals from the 2
nd
passage (Figure 2). However, in contrast to the animals from the
2
nd passage, the frontal cortex showed prominent diffuse synaptic
PrP immunoreactivity and perineuronal PrP deposition (Figure 6).
Upon development of clinical disease in animals from the 3
rd
passage, a dramatic increase in synaptic PrP immunoreactivity was
observed in all examined regions, including the hippocampus,
frontal cortex, thalamus, and granular layer of the cerebellum
(Figures 3C and 6). In the animals from the 2
nd LOTSS passage,
only a few brain regions showed weak synaptic PrP immunore-
activity indicating that this pathological hallmark had been
evolving with serial transmission (Figures 2 and 4C). Furthermore,
the progression of clinical disease was accompanied by accumu-
lation of prominent perineuronal PrP deposition in the deeper
layers of the frontal cortex (Figure 6) and thalamus. During the
clinical course, the smaller plaques or granular deposits in the
subependymal areas evolved into large plaques (Figure 6). In
addition, at the terminal stage, perivascular miniplaques appeared
in the cerebellum and brainstem (Figure 6 C, D and E).
Overall, LOTSS 3
rd passage presented with a quantitative and
qualitative change in the neuropathological phenotype. While
subependymal plaques were observed in animals from both 2
nd
and 3
rd passages, the animals of the 3
rd passage were characterized
by substantially more pronounced PrP immunoreactivity including
immunopositivity in the regions that did not show any PrP
deposition in LOTSS 2
nd. In addition, prominent diffuse synaptic
and perineuronal PrP deposition appeared as a correlate for the
clinical symptoms in LOTSS 3
rd indicating that the lack of clinical
disease in 2
nd passage could be attributed to the limited synaptic
deposition. These results suggest that LOTSS pathological features
evolve over substantial time period, which might take several serial
passages. Comparisons of PrP immunoreactivity score shows that
new brain regions including frontal layers, hippocampus and
cerebellum became involved during the 3
rd passage (Figure 3B).
The lesion profile obtained by averaging the spongiform changes,
neuronal loss and gliosis was found to be very similar in LOTSS-
Figure 5. Evolution of PrPres during LOTSS serial transmission. (A) Western blotting of BHs of animals from the 1
st,2
nd,o r3
rd passages of
LOTSS stained with SAF-84 antibodies. Animals from the 1
st and 2
nd were euthanized at 661 days postinoculation in the absence of clinical disease,
whereas animals from the 3
rd passage were euthanized at the beginning of first clinical signs, i.e. 307 days postinoculation (lanes 4, 5 and 6), or at the
end of the terminal stage (lanes 7, 8). Overexposed Western blot with 13 kDa atypical PrPres fragment is shown in bottom panel. Dashed line marks
the central position of the atypical 16 kDa band. Undigested 10% NBH is provided as a reference. (B) Schematic representation of the dynamics in
PrPres profile during serial transmission, where gray boxes represent atypical PrPres, whereas black boxes represent standard PrPres.
doi:10.1371/journal.ppat.1002419.g005
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other hamster strains suggesting that LOTSS and SSLOW belong
to the same family of strains (Figure 3A).
Preparation of rPrP amyloid fibrils lacks any detectible
PrP
Sc
Two alternative mechanisms can be put forward to explain the
low success rate in triggering transmissible prion disease by rPrP
amyloid fibrils. According to one mechanism, the preparations of
rPrP amyloid fibrils contain very small amounts of PrP
Sc or
particles with the structure of authentic PrP
Sc. If this is true, the
low success rate and long silent stage of the disease are attributed
to the long time required for amplification of this extremely small
amount of PrP
Sc. An alternative mechanism postulates that there
are no PrP
Sc particles in the preparations of amyloid fibrils.
Instead, amyloid fibrils, while structurally different from PrP
Sc
Figure 6. Comparison of PrP deposition at the early and late stages of the disease during the 3
rd passage. PrP deposition in frontal
cortex, cerebellum or subependymal areas in two animals euthanized at 307 days postinoculation (A, B), and three animals euthanized at the
terminal stage of the disease at 494, 521, and 494 days postinoculation (C, D, and E, respectively). Scale bar upper left represents 40 mm for all except
for the right panels of the frontal cortex and subependymal images where it represents 5 mm. Arrowheads indicate perineuronal deposits, double
arrowhead indicates fine synaptic immunoreactivity and arrows indicate granular immunoreactivity around ependymal cells.
doi:10.1371/journal.ppat.1002419.g006
Genesis of Mammalian Prions
PLoS Pathogens | www.plospathogens.org 8 December 2011 | Volume 7 | Issue 12 | e1002419[14–17], nevertheless are capable of triggering formation of PrP
Sc
when inoculated into animals. In this case, the low success rate and
silent stage of the disease are attributed to inefficient seeding of
PrPres by recombinant PrP amyloids and subsequent evolution of
PrPres structural and biological features, a process that eventually
give rise to PrP
Sc.
To distinguish between two mechanisms, we employed
sPMCAb that can detect miniscule amounts of PrP
Sc. In the first
series of experiments, we tested whether miniscule amounts of
LOTSS PrP
Sc could be efficiently detected by sPMCAb. 10% BHs
prepared from the 2
nd passage of LOTSS were diluted in ten fold
serial steps, then aliquots from each dilution were used to seed
sPMCAb reactions (Figure 7A). In 100 ml of PMCAb reaction
volume, 10
9- and 10
10-fold diluted LOTSS brain material was
detected with 100% and 83% success rate, respectively (Figure 7B).
The reactions seeded with brain material diluted to 10
11-fold or
higher were all negative. Six sPMCAb rounds were sufficient for
amplification of the highest dilutions of LOTSS brain material to
the level detectible by Western blot. Non-seeded normal BH
subjected to six sPMCAb rounds were all negative illustrating that
positive signals were not due to spontaneous formation or cross-
contamination (Figure S1C). As judged from the fitting of
experimental data on sPMCAb amplification of serially diluted
LOTSS brain material (Figure 7B), a PMCAb50 titer was found to
be 10
10.26 (Figure 7B). This value represents a dilution fold at
which there is a 50% chance of finding at least one PMCAb-active
PrP
Sc particle capable of initiating PMCAb amplification per
100 ml of the reaction volume. This experiment demonstrated that
the sPMCAb format employed here can effectively detect
miniscule amounts and, presumably, as little as a single LOTSS
PrP
Sc particle.
In the next series of experiments, sPMCAb was employed for
detecting PrP
Sc in the preparations of rPrP amyloid fibrils
subjected to annealing in the presence of BSA. Eleven sPMCAb
reactions seeded with rPrP amyloid fibrils from two independent
amyloid preparations were conducted. No positive signals were
detected in any reactions after six sPMCAb rounds (Figure 7C). As
judged from the previous experiment on PMCAb titration, six
sPMCAb rounds were sufficient for detecting LOTSS PrP
Sc at the
level of a single particle in 100 ml of the reaction volume.
To rule out the possibility that the negative result in detecting
PrP
Sc in the preparations of amyloid fibrils was due to the
inhibitory effect of fibrils on amplification of PrP
Sc, sPMCAb
reactions were seeded with rPrP amyloid fibrils mixed with 10
9-
fold diluted LOTSS brain material. 10
9-fold diluted brain material
represents the highest dilution at which 100% sPMCAb reactions
Figure 7. Preparations of rPrP fibrils have no detectible PrP
Sc. PMCAb titration of LOTSS brain material (A and B). (A) LOTSS brain material
was serially diluted to up to 10
13-fold and each dilution was subjected to six rounds of sPMCAb. Representative results are shown on Western blot
stained with 3F4 antibody. Undigested 10% NBH is provided as a reference. (B) For each dilution of brain material, the fractions of sPMCAb reactions
with a positive signal on Western blot were plotted against the logarithm of dilution (N) and non-linear least-square regression to a sigmoidal
function (black solid line, R=0.9999) was used to calculate PMCAb50 titer. (C) sPMCAb reactions were seeded with two independent preparations of
BSA-annealed rPrP amyloid fibrils (lanes 2–7 with amyloid I or lanes 16–20 with amyloid II), 10
9-fold diluted LOTSS brain material (lanes 9, 10), or with
amyloid fibrils II and 10
9-fold diluted LOTSS brain material (lanes 11–14), then six rounds of sPMCAb were conducted for each condition. The final
concentraton of rPrP amyloid fibrils in sPMCAb reaction was 10 mg/ml for amyloid I or 5 mg/ml for amyloid II. Two non-seeded reactions are shown as
negative control. Brains from LOTSS-inoculated animals from the 2
nd passages were used for all experiments. Undigested 10% NBH is provided as a
reference. Western blots were stained with 3F4.
doi:10.1371/journal.ppat.1002419.g007
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dent sPMCAb reactions were conducted and all gave a positive
signal on Western blot (Figure 7C). This experiment confirmed
that the presence of rPrP fibrils did not diminish the sensitivity of
detection of LOTSS PrP
Sc by sPMCAb. Taken together, these
experiments revealed that the preparations of rPrP amyloid fibrils
do not contain any PrP
Sc particles that could be detected by
sPMCAb providing strong support for the second mechanism. In
our experience and consistent with the previously published data
[24], sPMCAb is ,400 to 4000 fold more sensitive than bioassay.
Transition from rPrP fibrils to LOTSS PrP
Sc
During serial transmission of LOTSS, we observed a dynamic
transformation of the PK-resistant band pattern. PrPres consisted
of atypical C-terminal fragments at the 1
st passage, and then
atypical PrPres shifted to a predominantly 21–30 kDa PK-
resistant core typical for PrP
Sc at the 3
rd passage (Figures 1B
and 5). To determine whether the atypical PrPres encompasses the
same region as the PK-resistant core of rPrP fibrils, BH from the
animal of the 1
st passage was treated with PNGase F to remove
carbohydrates. The PK-resistant core of annealed rPrP fibrils was
previously found to consists of two major fragments of ,138–231
and 152/153–231 [18,25]. Upon treatment with PNGase F, the
three PK-resistant bands of 21, 16 and 13 kDa merged into a
single band of ,13 kDa illustrating that these three bands
represent di-, mono- and unglycosylated forms of a single PK-
resistant fragment (Figure 8). This C-terminal fragment reacted
with R1 (epitope 225–231) and SAF-84 (epitope 160–170), but not
with 3F4 (epitope 109–112) or D18 (epitope 133–157) antibodies
(Figures 1A, and 8A and B). Therefore, the atypical PrPres
fragments matched the lower PK-resistant band of the fibrillar
core that encompassed resides 152/153–231. The difference
between PAGE-mobility of the rPrP 152/153–231 fragment and
13 kDa atypical PrPres fragment was likely due to a GPI-anchor in
the last one. This result supports the hypothesis that the structure
of LOTSS PrPres originated from rPrP fibrils.
Together with previous data (Figure 1), the results on epitope
mapping illustrate that a dynamic transformation of LOTSS
PrPres occurred during three serial passages. This transformation
involved an increase in the size of the PK-resistant core from the
atypical PrPres to the one typical for authentic PrP
Sc. Notably, the
change in size was accompanied by a significant shift in the ratio of
three PrP glycoforms recruited by PrPres. While atypical PrPres
preferred monoglycosylated PrP (16 kDa band, Figure 1B),
standard PrPres at the 3
rd passage favored a diglycosylated PrP
(Figure 1B and D), a feature common for all previously known
hamster strains.
Discussion
In the current work, transmissible prion disease was generated
in wild type animals upon inoculation of rPrP amyloid fibrils
produced in vitro in the absence of a cellular environment or co-
factors. When triggered by recombinant fibrils, only a small
fraction of animals showed signs of infection. Furthermore, it took
two additional serial passages for a fully developed disease with a
distinct set of symptoms to evolve. Two alternative models could
be put forward to explain the low success rate in infecting the
animals by rPrP fibrils (Figure 9). According to the first model, the
preparations of rPrP amyloid fibrils contain very small amounts of
PrP
Sc or particles with a structure of authentic PrP
Sc (Figure 9A).
The second model proposes that the formation of PrP
Sc and
emergence of transmissible prion diseases could be triggered in
wild type animals by seeding material that lacks PrP
Sc (Figure 9B).
This model takes into consideration previous data that showed
that the structures of PrP
Sc and rPrP fibrils are fundamentally
different as evident from X-ray diffraction analysis [14,17], FTIR
spectroscopy [26,27], AFM and EM imaging and seeding-
Figure 8. Analysis of the C-terminal PrPres fragments. Western blot of PK-digested BH from the animal inoculated with BSA-annealed rPrP
amyloid fibrils (lanes 1, 2) or BSA-annealed rPrP amyloid fibrils (lanes 3 and 4) stained with SAF-84 (panel A) or D18 (panel B) antibodies. BH in lane 2
was treated with PNGase F. Before PK digestion, rPrP fibrils were mixed with 10% NBH to balance the condition for PK digestion. Samples in lanes 1, 2
and 3 were treated with 20 mg/ml of PK, and the sample in lane 4 – with 10 mg/ml of PK. Western blot was stained with SAF-84.
doi:10.1371/journal.ppat.1002419.g008
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fibril-induced seeding of PrP
Sc is not efficient, which could explain
the low rate of infection in the first passage. For the same reasons,
transformation of the rPrP amyloid structure into PrP
Sc structure
might involve several steps before fully infectious authentic PrP
Sc
emerges, yielding the long silent stage to clinical disease.
The results of the current and previously published studies
strongly support the second model. First, no PrP
Sc was found in
the preparations of rPrP amyloid in an assay format that detects
miniscule amounts of prions. One could argue that the efficiency
of prion amplification and the sensitivity of detection in sPMCAb
are strain-specific. We found that the efficiency of LOTSS PrP
Sc
amplification in sPMCAb was similar to that of 263 K PrP
Sc
(Figure 3SA). 100% and 83% of sPMCAb reactions seeded with
asymptomatic LOTSS brains serially diluted 10
9 or 10
10-fold,
respectively, were positive, whereas all reactions seeded with 10
11-
fold and higher dilutions were negative (Figure 7). This result
suggests that the limiting dilution was reached in the experiment
on sPMCAb titration. It also illustrates that 10
10-fold diluted
LOTSS brain material has only one or very few PMCAb-active
PrP
Sc particles per 100 ml of the reaction volume, and that these
quantities of LOTSS PrP
Sc could be effectively detected in our
assay format. If one assumes that the first model is correct, the
amount of infectivity per 50 ml of inoculum should be equivalent
to approximately 0.5–1 infectious dose to account for the low
infection rate in the first passage (3 out of 7 animals). This amount
of infectivity is equivalent to ,10,000–100,000 PrP molecules or
to ,100–1000 PrP
Sc particles, assuming that an average PrP
Sc
particle consists of ,100 PrP molecules [24]. This amount of
PrP
Sc is well above the detection limits of sPMCAb, and should
have been easily detected if present in preparations of rPrP fibrils.
Second, the experimental protocol used for producing rPrP
amyloid fibrils employs denaturants (a mixture of 1M GdnHCl
and 3M urea) - solvent conditions under which PrP
Sc undergoes
denaturation. Because rPrP fibrils are much more conformation-
ally stable than PrP
Sc [6,21,28], rPrP fibrils can be formed under
solvent conditions where PrP
Sc is largely denatured. Furthermore,
conversion of PrP
C into authentic PrP
Sc in vitro requires RNA and
lipids [9,10], whereas rPrP amyloid fibrils were formed in the
absence of any cellular co-factors. Therefore, it is highly unlikely
that PrP
Sc particles with authentic structures could be formed
during the preparation of rPrP fibrils conducted in the absence of
co-factors essential for authentic PrP
Sc structures and under
solvent conditions that promote PrP
Sc denaturation.
Third, when transmissible prion disease is triggered by rPrP
amyloid fibrils, a decrease in PrP
Sc conformational stability was
observed during serial passages of synthetic prions [6,29]. Similar
dynamics in PrP
Sc conformational stability was observed regard-
less of whether transgenic mice or Syrian hamsters were used for
inoculating rPrP fibrils suggesting that a common pathway in the
genesis and evolution of transmissible prion protein structures
might exist [6,29]. Observed changes in the physical properties
illustrate that PrP
Sc structure undergoes transformation during
serial passages providing a direct support for the second model.
Fourth, the first model has difficulties in explaining two silent
passages. While the first silent passage could be attributed to the
low titer of infectious material in the preparation of rPrP fibrils, it
is challenging to explain the second silent passage without
assuming that the neurotoxic properties of LOTSS PrP
Sc are
evolving slowly. Together with a dynamic change in PK-resistant
profile, the second silent passage is indicative of transformation in
PrPres structure and its neurotoxic features, which is consistent
with the second model.
Fifth, significant quantitative and qualitative changes in PrP
deposition were observed during LOTSS serial transmission. In
animals from the 2
nd passage, LOTSS-specific PrP was predom-
inantly found in the form of subpial and subependymal plaques,
whereas animals from the 3
rd passage showed a dramatic increase
in diffuse synaptic immunoreactivity and perineuronal deposition
in addition to plaques. Furthermore, involvement of new brain
regions positive for PrP immunostaining was observed during the
serial passage of LOTSS, pointing out possible changes in strain
neurotropism, which again is consistent with a dynamic transfor-
mation in PrPres biological and physical features. Previously, a
change in the pattern of PrP accumulation was found to
accompany strain adaptation during serial transmission in a new
host [30]. The changes in neurotropism or distribution pattern
could not be attributed solely to an increase in the total amounts of
LOTSS PrPres, because certain brain regions including frontal
deeper layers, hippocampus and granular cerebellum displayed a
Figure 9. Schematic representation of two mechanisms responsible for generating transmissible prion diseases de novo. According
to the first mechanism (A), the preparations of rPrP amyloid fibrils contain very small amounts of PrP
Sc. The silent stage of the disease is attributed to
the long time required for amplification of this extremely small amount of PrP
Sc. A second mechanism referred to as deformed templating postulates
that there are no PrP
Sc particles in the preparations of amyloid fibrils (B). Instead, when inoculated into animals, amyloid fibrils can seed conversion of
PrP
C into PrPres, although with a low efficiency. PrPres undergoes slow transformation, a process that might require long silent stage, before
authentic PrP
Sc emerges.
doi:10.1371/journal.ppat.1002419.g009
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PrP deposition in the 3
rd passage despite a shorter life span.
Sixth, in recent studies on synthetic prions, a strong correlation
between conformational stability of rPrP amyloid fibrils, the
stability of PrP
Sc produced in animals upon inoculating rPrP fibrils
and the incubation time to disease was described [5]. If a miniscule
fraction in the preparation of rPrP fibrils is responsible for the
disease, the correlation between stability of rPrP amyloid, which is
a bulk property of fibril preparation, and PrP
Sc would be
challenging to explain. Again, these results provide a strong
support for the second model.
Seventh, as judged from clinical and neuropathological features,
both synthetic strains generated de novo upon inoculating Syrian
hamsters with rPrP fibrils (LOTSS and SSLOW) were remarkably
different from all previously known rodent strains including those
generated in sPMCA [8–10]. Among the most distinguishable
LOTSS and SSLOW features were the long incubation time to
and slow progression of clinical disease, accumulation of large
plaques in subpial and subependymal areas, distinctive lesion and
PrP immunoreactivity profiles and unusual clinical phenotype
(obesity, hair loss). The fact that SSLOW and LOTSS can be
separated into a distinct class of prion strains remarkably different
from strains produced in sPMCA or isolated from animals is
consistent with the hypothesis that SSLOW or LOTSS PrP
Sc
originated from unique structures or rPrP fibrils.
Eighth, observation of the atypical, C-terminal, low molecular
weight PK-resistant products in the first passage strongly supports
the last conclusion. Both, atypical PrPres and rPrP fibrils had very
similar if not identical PK-resistant cores that encompassed
epitopes for SAF-84 and R1, but not 3F4 antibodies [18,25].
This result supports the idea that the structure of fibrillar rPrP
gave origin to LOTSS PrPres.
Ninth, the transformation in LOTSS PrPres structure is
demonstrated by an increase in the size of the PK-resistant core
from atypical to standard and the change in glycosylation
preferences. This transformation provides direct support for the
second model. While atypical PrPres predominantly recruited
monoglycylated PrP, the LOTSS PrP
Sc preferred diglycosylated
PrP, a feature which is common for all currently known hamster-
adapted prion strains.
All the data on synthetic prions accumulated to date support
the hypothesis that transmissible prion diseases can be triggered
by PrP structures substantially different from that of authentic
PrP
Sc and in the absence of PrP
Sc in preparation of rPrP fibrils
(Figure 9 B). This hypothesis assumes that only a partial overlap
or distant similarities in structures of fibrillar rPrP and PrP
Sc are
sufficient for triggering transmissible prion diseases in animals.
While the precise mechanistic details for inducing PrP
Sc
formation by conformationally different PrP structures remain
to be elucidated, the model of conformational switching provides
one possible explanation of how such transformation occurs
[31,32]. According to this model, the global folding pattern of
PrP molecules within amyloid fibrils and PrP
Sc are different,
nevertheless, they share a common structural motif. For instance,
a common b-strand that can link two structures provides
opportunity for limited templating. This model is consistent with
experimental observations that the global structures of PrP
Sc and
rPrP fibrils are different [14,15,17], and explains that there is a
correlation between conformational stability of two structures [5].
Because of only partial overlap between the two structures, the
seeding of PrP
Sc by rPrP fibrils is inefficient, which explains the
low infection rate in the first passage. Previous studies on
molecular imaging of single amyloid fibrils provided a proof of
principle that the conformational switching between two
alternative PrP folding patterns can occur within an individual
PrP fibril or particle [31].
The current study proposes that a new mechanism designated
as ‘deformed templating’ that is different from the classical
templating might exist. In classical templating, the folding pattern
of a newly recruited polypeptide chain accurately reproduces that
of the template. In deformed templating, while the template
provides limited seeding, a newly recruited polypeptide chain
acquires a new folding pattern which only partially overlaps with
the folding pattern of the template. Two glycosyl groups and a GPI
anchor present in PrP
C might impose steric constraints on the
spectrum of folding patterns available to PrP
C, therefore providing
a driving force behind switching PrP folding patterns from rPrP
fibril-specific to PrP
S-specific. In fact, the evolution of PrP
Sc
structure might involve at least two steps. The first step involves a
transformation of the fibrillar rPrP structure to the structure of
atypical PrPres, which is characterized by a short PK-resistant
core, a preference for monoglycosylated PrP, and inactivity in
PMCAb. We do not know how long it took for the transition from
fibrillar rPrP to atypical PrPres to occur in animals. The second
step is a transformation from atypical PrPres to LOTSS PrP
Sc that
displays a standard PK-resistant core, favors diglycosylated PrP, is
PMCAb-active and shows RNA-dependency in sPMCAb ampli-
fication.
If the hypothesis that a fibril-specific PrP folding pattern can
template a distinct folding pattern within PrP
Sc is correct, one can
assume that the opposite reaction, i.e. the seeding of rPrP fibrils by
PrP
Sc is also possible. Indeed, several assays exploited the
phenomenon of PrP
Sc-seeded conversion of a-rPrP into amyloid
fibrils for detecting miniscule amounts of PrP
Sc [33,34]. Interest-
ingly, the structure of rPrP fibrils produced as a result of seeding by
PrP
Sc only distantly resembled those of PrP
Sc structure and had
limited infectivity [35].
Although a number of unique features warrant classification of
SSLOW and LOTSS into a separate class of prion strains, PrP
Sc of
both synthetic strains was predominantly diglycosylated, and
PMCAb amplification of both strains showed strong RNA
dependency, features that were common with other hamster
strains [22,23]. Interestingly, the RNA dependency in LOTSS
amplification emerged during the first passage (Figure 1C),
whereas the first clinical signs were observed only during the 3
d
passage. These results suggest that the two stages in the evolution
of PrP
Sc structure – (1) transformation of fibrillar structure, which
is RNA independent, into a structure that relies on RNA in self-
replication and (ii) acquiring neurotoxic features essential for
clinical disease, are separated. Dramatic increase in diffuse
synaptic PrP immunoreactivity at the 3
rd passage suggests that
the clinical expression of the disease might require synaptic PrP
deposition. The mechanism underlying significant changes in the
PrP deposition pattern during LOTSS serial transmission and
possible connections between changes in PrP
Sc structure and its
deposition pattern remain to be explored in future studies.
Inter-species prion transmission to new hosts including human is
known to involve a long clinically silent stage that accompanies an
adaptation to a new host [36,37]. In the case of inter-species
transmission, the long silent stage, which is referred to as a
transmission barrier, is attributed at least in part to the differences
in amino acid sequence of host PrP
C and donor PrP
Sc. Moreover,
the cross-species barrier could also be due to change in preferences
for species-specific cofactors in prion replication [23]. Despite
identity in the amino acid sequence of the rPrP inoculum and host
PrP
C, the silent stage in the current studies was found to be very
long and consisted of two passages. Such a long silent stage is
presumably attributable to the evolution of PrP
Sc physical and
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associated with inter-species transmission despite the fact that no
change in the same amino acid sequence was involved. Consistent
with this view, FTIR and X-ray diffraction analysis revealed that
PrP
Sc isolated from different species display very similar folding
patterns, which appear to be fundamentally different from the PrP
folding pattern within rPrP fibrils [17,26,27,38].
In other studies on inter-species transmission including the work
on transmission of BSE to wild type mice or transmission of the
hamster-adapted strain 263 K to transgenic mice carrying murine
PRNP gene with a mutation P101L [39,40], the clinical disease was
observed in the first passage but in the absence of detectable
amounts of PrPres. In the current studies, the second passage of
LOTSS produced large amounts of PrPres, however, without any
detectible clinical symptoms. Both sets of data were consistent with
the emerging hypothesis that infectious and neurotoxic PrP species
might be two different entities [41].
Much of the public health risk from prion diseases derives from
their long asymptomatic incubation times [42]. During the
asymptomatic period humans pose a real risk of spreading the
infection through invasive medical procedures or tissue or blood
donation [43]. The current work raises the importance of using
antibodies against several PrP regions including the C-terminal
region for effective diagnosis of prion diseases. Noteworthy, C-
terminal PK-resistant fragments with a length similar to that of
atypical PrPres described here were found in a majority of
individuals with sporadic CJD [44]. If asymptomatic stages are
accompanied by accumulation of predominantly atypical PrPres,
while the procedures that rely only on N-terminal antibodies such
as 3F4 are employed, the pathogenic process would remain
undetected. This study raises a great concern that transmissible
prion diseases can be triggered by protein structures which are
considered to be not-infectious. Furthermore, spread of transmis-
sible, disease-related prion structures can occur undetected during
a silent stage of prion evolution when no clinical expression of the
disease can be observed.
The hypothesis that transmissible prion diseases can be
triggered by cross-b PrP structures substantially different from
that of authentic PrP
Sc has large implications for understanding
the ethiology of prion and, possibly, other neurodegenerative
diseases. Several recent studies documented that amyloid forms of
several proteins linked to neurodegenerative diseases were capable
of seeding their own aggregation in a prion-like manner in a cell
and spreading from cell to cell through the nervous system
(reviewed in [45–47]). The recent study provided the first
illustration that pathological changes associated with non-prion
neurodegenerative diseases could be induced or transmitted
through inoculation of the aggregated forms of non-prion proteins
such as Ab [48]. Furthermore, a growing amount of evidence
illustrates that amyloids can template structures different from
their own [31]. It is generally assumed that self-perpetuating
aggregation requires identity in amino acid sequence between
seeds and substrate. An increasing number of studies, however,
suggest the possibility of cross-talk between non-related amyloido-
genic proteins [49–51]. In vivo, amyloidosis of one protein was
found to be triggered by fibrils of an unrelated protein in a manner
similar to cross-seeded polymerization [49–51]. Cross-talk be-
tween several yeast prion proteins provides another example of
how direct interactions between newly forming and pre-existing
heterologous fibrils might take place in a cell [52–54]. Moreover,
pathological studies revealed that protein aggregates produced
from two different proteins or peptides, including PrP, Ab, a-
synuclein, immunoglobulin light chain l, and b2 microglobulin
often co-localize within the same amyloid plaques in a variety of
organs or tissues [55–59]. The promiscuous nature of the
propagating activity of amyloid structures can lead to devastating
consequences. For instance, cross-talk between non-related
amyloidogenic proteins may offer a possible explanation for
development of the age-related conformational disorders that are
considered to be sporadic. It would be interesting in future studies
to define the spectrum of structures and sequences capable of
triggering PrP
C to PrP
Sc conversion and induce transmissible prion
diseases.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of the University of Maryland, Baltimore (Assurance
Number A32000–01; Permit Number: 0309001).
Expression and purification of rPrP and formation of rPrP
fibrils
Syrian hamster full-length recombinant PrP encompassing
residues 23–231 (rPrP) was expressed and purified according to
the previously described procedure [60] with minor modifications
[6]. Lyophilized rPrP was dissolved in 6 M GdnHCl to prepare a
3 mg/ml stock solution of rPrP. To form fibrils, the rPrP stock
solution was diluted to a final protein concentration of 0.5 mg/ml
and incubated at 37uC in 20 mM sodium acetate (pH 5.0), 1 M
GdnHCl, 3 M Urea, 150 mM NaCl, 10 mM EDTA for 4 days
with continuous horizontal shaking at 600 rpm. Amyloid forma-
tion was confirmed by increased Thioflavin T fluorescence and
electron microscopy [60]. Fibrils were dialyzed into 10 mM
sodium acetate, pH 5.0.
To perform annealing, rPrP fibrils at 0.1 mg/ml were heat-
treated in PBS, pH 7.4, in the presence of 5 mg/ml BSA (Sigma,
catalog #A3294) and 0.1% Triton X-100 using the following
procedure: 50 ml aliquots in thin-wall PCR tubes with domed caps
were placed into the PCR machine and subjected to 5 cycles of
1 min incubation at 80uC followed by 1 min incubation at 37uC.
All aliquots were pooled together and the combined volume was
immediately transferred to the animal facility for inoculation.
Bioassay
For the first passage, weanling Syrian hamsters were inoculated
intracerebrally with the preparation of rPrP fibrils described
above. Each animal was anesthetized with interperitoneal
pentobarbital before receiving 50 ml of inoculum. Hamsters were
observed daily for disease starting from the third month
postinoculation. They were euthanized at 661 days post
inoculation without any signs of clinical disease, their brains
removed aseptically and saved for subsequent passage and
analysis.
For the second and third passages, 10% BHs prepared by
sonication in PBS, pH 7.4 (see below), were dispersed by an
additional 30 sec of sonication immediately before inoculation.
Each hamster received 50 ml of inoculum intracerebrally under
general anesthesia (2% O2/4 MAC isoflurane). After inoculation,
hamsters were observed daily for disease.
Proteinase K digestion
Brains were collected aseptically and cut in half with disposable
scalpels. One half was used to prepare 10% BHs, while the second
half was stored at 280uC for future analysis or fixed in formalin
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pH 7.4, with a Sonics vibra cell VCX750 (Newtown, CT) tip
sonicatior fitted with a stepped microtip by 2 pulses of 30 sec
sonication with 30 sec cooling on ice between the pulses. For the
Proteinase K digestion in sarcosyl, an aliquot of 10% brain
homogenate was mixed with an equal volume of 4% sarcosyl in
PBS, supplemented with 50 mM Tris, pH 7.5, and digested with
20 mg/ml PK for 30 min at 37uC with 1000 rpm shaking
(Eppendorf Thermomixer). Alternatively, 1% brain homogenate
in conversion buffer was supplemented with 0.25% SDS and
50 mg/ml PK and digested at 37uC for 1 hour. Proteinase K
digestion was stopped by adding SDS sample buffer and heating
the samples for 10 min in a boiling water bath. After loading onto
NuPAGE 12% BisTris gels and transfer to PVDF membrane, PrP
was detected with 3F4 (epitope 109–112), D18 (epitope 133–157),
SAF-84 (epitope 160–170), or R1 (epitope 225–231) antibody, as
indicated. For PK digestion of recombinant fibrils annealed in
BSA, fibrils were diluted to 10 mg/ml in 1% NBH supplemented
with 0.25% SDS and digested with 10 or 20 mg/ml PK for 1 hour
at 37uC.
Deglycosylation of PrPres
Removal of N-linked glycans was performed as previously
described [61], using glycerol free PNGase F and supplied buffers
(New England BioLabs). 5% BH in sarcosyl was digested with
20 mg/ml Proteinase K as described above. After termination of
PK digestion with 2 mM PMSF, the resulting 36 ml of digest was
supplemented with 4 ml of 10x glycoprotein buffer and heated at
95uC for 10 min. After heat-treatment, 5 ml of 10xG7 reaction
buffer, 5 ml of 10% NP-40, and 3 ml of PNGase F enzyme were
added, and the samples were incubated overnight at 37uC. The
next day, the samples were boiled for 10 min in SDS sample buffer
(Invitrogen) and loaded onto NuPAGE 12% BisTris gels. After
transfer to PVDF, PrP was detected with SAF-84 or D18 antibody
as indicated.
Conformational stability assay
10% brain homogenates were sonicated for 30 sec at 50% power
efficiency within Misonix-4000 microplate horn filled with 350 ml
water. Then the samples were diluted to 1% BH with conversion
bufferand incubated with variousconcentrations ofGdnHClwithin
96 Deep Well 1 ml plate (Fisher #12–566–120) for 1 hour at room
temperature. After incubation, all samples were diluted with PBS to
A final concentration of GdnHCl of 0.4 M and incubated for an
additional 1 h at room temperature. The incubation was followed
by loading 50 ml of each denaturation point onto a nitrocellulose
membrane using a BioDot microfiltration apparatus (Bio-Rad)
accordingto the manufacturer’ manual. After two washeswith PBS,
the membrane was removed from the apparatus, immediately
blocked with 2.5% non-fat milkinPBSTfor30 min, incubatedwith
antibody overnight at +4uC, and developed according to the
common immunodetection protocol.
To compare relative exposure of 3F4 and SAF-84 epitopes in
LOTSS, SSLOW and 263 K, equal amounts of brain homoge-
nates were denatured with 5 M GdnHCl and loaded onto
nitrocellulose membrane with a BioDot apparatus. To eliminate
the possibility of PrP
C influencing the data, the relative exposure of
epitopes was also analyzed after mild denaturation with 1 M
GdnHCl and PK digestion. Chemiluminescent signals were
measured by a Typhoon 9200 variable mode imager.
Protein misfolding cyclic amplification
Healthy hamsters were euthanized and immediately perfused
with PBS, pH 7.4, supplemented with 5 mM EDTA. Brains were
dissected, 10% brain homogenate (w/v) was prepared using ice-
cold conversion buffer and glass/Teflon tissue grinders cooled on
ice and attached to a constant torque homogenizer (Heidolph
RZR2020). The brains were ground at low speed until
homogeneous, then 5 additional strokes completed the homoge-
nization. The composition of conversion buffer was as previously
described [62]: Ca
2+-free and Mg
2+-free PBS, pH 7.5, supple-
mented with 0.15 M NaCl, 1.0% Triton, and 1 tablet of Complete
protease inhibitors cocktail (Roche, Cat# 1836145) per 50 ml of
conversion buffer. The resulting 10% NBH in conversion buffer
was precleared by 2 min centrifugation at 500 g and the resulting
supernatant was used as the substrate in PMCA with beads
(PMCAb) reactions [19]. 100 ml samples in 0.2 ml thin-wall PCR
tubes containing 3 Teflon 3/32’’beads (McMaster-Carr
#9660 K12) were placed in a floating rack inside Misonix-4000
microplate horn sonicator, filled with 350 ml water. Two coils of
rubber tubing attached to a circulating water bath were installed
for maintaining 37uC inside the sonicator chamber. The standard
sonication program consisted of 30 sec sonication pulses delivered
at 50% power efficiency applied every 30 min during a 24 hours
period, therefore, each round consisted of 48 cycles. For each
subsequent round, 10 ml of the reaction from previous round were
added to the 90 ml of a fresh substrate. To produce RNA-depleted
BH, precleared NBH was incubated with 100 mg/ml RNase A
(Sigma, Cat. # R-4875) for 1 hour at 37uC prior to its use as a
substrate in PMCAb. Complete digestion was confirmed using
RNA content analysis in 1.2% Agarose gel and ethidium bromide
staining.
For the titration experiment, 100 ml aliquots of 10% BH were
sonicated with 3 Teflon 3/32’’ beads for 30 sec in PMCA
conditions before serial 10-fold dilutions into conversion buffer.
sPMCAb titration was done for two animals from the 2
nd passage
of LOTSS. To determine PMCAb50 values, nonlinear least-square
regression analysis of the data to the following equation was
performed in Sigma Plot:
F~ 100   exp { AzB   x ðÞ ðÞ ðÞ = 1zexp { AzB   x ðÞ ðÞ ðÞ
where F is percent of positive PMCAb reactions, x is the logarithm
of the dilution fold, and A and B are two fitting parameters that
define the position of a limiting dilution transition on the x axis
and the slope of the transition, respectively. PMCAb50 was
calculated according to the equation:
PMCAb50~A=B:
To analyze production of PK-resistant PrP material in PMCA,
10 ml of the sample were supplemented with 5 ml SDS and 5 ml
PK, to a final concentration of SDS and PK of 0.25% and 50 mg/
ml respectively, followed by incubation at 37uC for 1 hour. The
digestion was terminated by addition of SDS-sample buffer and
heating the samples for 10 min in boiling water bath. Samples
were loaded onto NuPAGE 12% BisTris gels, transferred to PVDF
membrane, and probed with 3F4 or SAF-84 antibodies.
Histopathological studies
Formalin fixed brain halves divided at the midline (right
hemisphere), spinal cord, and spleen, were processed for
hematoxylin-eosin stain as well as for immunohistochemistry for
PrP, using the mouse monoclonal anti-PrP antibody 3F4 (1:1000,
Covance, Berkeley, CA, USA) and anti-glial fibrillar acidic protein
(GFAP; 1:3000, Dako, Glostrup, Denmark). Blocks were treated in
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disease-associated PrP, we applied a pretreatment of 30 minutes
hydrated autoclaving at 121uC followed by 5 minutes in 96%
formic acid. We evaluated all tissues for the presence of
inflammation and PrP immunoreactivity, and the brain for the
presence of spongiform change and degree of gliosis. Degree of
spongiform change, neuronal loss and gliosis, and intensity of PrP
immunostaining were semiquantitatively evaluated (0: none; 1:
mild; 2: moderate; 3 severe) in the following anatomical regions as
previously described: frontal cortex, hippocampus, caudate-
putamen, thalamus, brainstem and cerebellum [6]. Lesion profiles
were obtained by averaging scores of spongiform change, neuronal
loss, and gliosis for each anatomical region and animal group.
Supporting Information
Figure S1 Analysis of BH from animals inoculated with
rPrP fibrils using sPMCAb. 10% BH from the animals
inoculated with BSA-annealed rPrP amyloid fibrils was diluted 10-
fold into 10% NBH and subjected to two (panel A) or six (panel B)
sPMCAb rounds. BH from animal #2 showed atypical PK-
resistant bands (Figure 1), from animal #6 showed PrPres after
one PMCAb round and from animal #7 - after six sPMCAb
rounds. Ten reactions, each consisted of six sPMCAb rounds, were
conducted in non-seeded NBHs as negative controls (panel C).
Each PMCAb round consisted of 48 cycles, 30 min each; 10-fold
dilutions were used for each subsequent sPMCAb round. Western
blot was stained with 3F4.
(TIF)
Figure S2 Analysis of BH from LOTSS-inoculated
animals of the 2
nd passage. Western blotting of the BHs
from the animals of 2
nd passage of LOTSS stained with 3F4 (top
panel) or SAF-84 (bottom panel). Animals # 1–5 and 7 showed
large amounts of standard and atypical PrPres (lanes 1–5 and 7,
respectively), whereas the animal #6 predominantly shows
atypical PrPres. BH from animal # 6 (lane 6) was subjected to a
single PMCAb round (lane 9).
(TIF)
Figure S3 Analysis of LOTSS PrP
Sc amplification rate in
PMCAb and resistance to PK. (A) BH from LOTSS- (top
panel) or 263 K-inoculated animals (lower panel) were diluted 10
4-
fold into 10% NBH and subjected to four sPMCAb rounds. The
material amplified in each round was diluted 30-, 100-, 300-, or
1000-fold into 10% NBH for the next PMCAb round, as
indicated. Undigested 10% NBH is provided as a reference. (B)
BHs from LOTSS- (top panel) or 263 K-inoculated animals
(bottom panel) were diluted to 1% in conversion buffer and treated
with increasing concentration of glycerol-free Proteinase K (Sigma
#P6556) in the presence of 0.25% SDS for 1 hour at 37uC.
Western blots were stained with 3F4. BH from the 2
nd passage of
LOTSS was used in both experiments.
(TIF)
Figure S4 Analysis of conformational stability. 1% BH
from animals inoculated with 263 K (panel A), SSLOW (panel B),
or LOTSS (panel C) was incubated with increasing concentrations
of GdnHCl from 0.4 to 4 M for 1 h, as indicated, then diluted out
of GdnHCl, equilibrated for 1 h at room temperature and
digested with 20 mg/ml PK, followed by addition of 2 mM PMSF
and precipitation with 4 volumes of cold acetone. Undigested
brain material exposed to 0.4 M GdnHCl is provided as a
reference. BHs from the 2
nd passages of SSLOW or LOTSS were
used. Western blotting was stained with 3F4.
(TIF)
Figure S5 Analysis of strain-specific SAF-84 to 3F4
immunoreactivity ratio. To compare relative immunoreac-
tivity of SAF-84 and 3F4 epitopes, BHs from LOTSS-, SSLOW-
or 263 K-inoculated animals were denatured with 5 M GdnHCl
and loaded onto nitrocellulose membrane with BioDot apparatus
(see methods) and stained with SAF-84 or 3F4 (panel A). To
eliminate the possibility of PrP
C influencing the results, we also
compared relative exposure of SAF-84 and 3F4 epitopes after mild
denaturation of BHs with 1 M GdnHCl followed by PK digestion
(panel B). Both methods show that the intensity ratio of SAF-84 to
3F4 in LOTSS-infected BH was significantly higher than that in
SSLOW- or 263 K-infectd BH. BHs from the 2
nd passages of
SSLOW or LOTSS were used. Data represent average 6 SD of
three replicas.
(TIF)
Table S1 Bioassay of rPrP amyloid fibrils in golden
Syrian hamsters and control experiments.
(DOC)
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